The drugmaker plans to develop a “flexible, modular campus” with advanced digital and automation technologies. The first phase is set to be ready in 2031.
What happened
Let Manufacturing Dive's free newsletter keep you informed, straight from your inbox.
Why it matters
The manufacturing site coming to New Albany is part of Bayer’s U.S. growth strategy. The biotechnology giant has spent more than $7 billion over the past five years expanding its U.S. pharmaceutical manufacturing and research and development operations.
“The facility will be a strong strategic addition to our global Product Supply Network,” Holger Weintritt, head of product supply at Bayer’s pharmaceutical division, said in a statement. “As we continue to invest in our existing manufacturing sites around the globe, our planned presence in Ohio will further enhance our ability to serve our markets with greater resilience and reliability.”
A spokesperson with Bayer did not immediately respond to a request for comment seeking details about the size of the New Albany facility, construction timeline or incentives the project may be eligible for.
This news brief is based on reporting published by Manufacturing Dive on 2026-10-06. The original report is linked below.
Manufacturing Dive
https://www.manufacturingdive.com/news/bayer-to-invest-2b-ohio-pharmaceutical-facility-new-albany/832237/This independent news brief is based on the public source identified above. It is an original summary or translation, not a reproduction of the source article. Rights in source text, research, trademarks and images remain with their respective owners; images are used under the licence or permission identified in the credit. Rights holders may contact rights@goodproductasia.com with evidence of ownership. Verified concerns will be corrected, replaced or removed promptly. This report is not investment, legal, medical or purchasing advice.
